Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data

Group 1 - Black Diamond Therapeutics is preparing to report initial results from its phase 2 study of BDTX-1535 targeting first-line EGFR mutant non-small cell lung cancer (NSCLC) patients in Q1 of 2025 [1] - There may be an additional update of data related to the study [1] Group 2 - The article mentions the author is associated with Biotech Analysis Central, which includes a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [1]